|
Report Date : |
04.06.2012 |
IDENTIFICATION DETAILS
|
Name : |
ARLAK BIOTECH PRIVATE LIMITED |
|
|
|
|
Registered
Office : |
H.No.671, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as
on) : |
31.03.2010 |
|
|
|
|
Date of
Incorporation : |
27.04.2007 |
|
|
|
|
Com. Reg. No.: |
16-031093 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Rs.0.300 million |
|
|
|
|
CIN No.: [Company Identification
No.] |
U24232PB2007PTC031093 |
|
|
|
|
TAN No.: [Tax Deduction &
Collection Account No.] |
PTLA13670G |
|
|
|
|
PAN No.: [Permanent Account No.] |
AAGCA5095C |
|
|
|
|
Legal Form : |
Private Limited Liability Company |
|
|
|
|
Line of Business
: |
Trader of Pharmaceuticals. |
|
|
|
|
No. of Employees
: |
20 (Approximately) |
RATING & COMMENTS
|
MIRA’s Rating : |
B (26) |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Maximum Credit Limit : |
USD 1400 |
|
|
|
|
Status : |
Small Company |
|
|
|
|
Payment Behaviour : |
Slow |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is a small company in its field. Its scale of activities are
limited. However, trade relations are reported as fair. Business is active.
Payments are reported to be slow. The company can be considered for small business dealings with some
cautions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
INFORMATION PARTED BY
|
Name : |
Mr. Umesh Roshan Lal Kalra |
|
Designation : |
Director |
|
Contact No.: |
91-9888885355 |
|
Date : |
12.05.2012 |
LOCATIONS
|
Registered Office : |
H.No.671, |
|
Tel. No.: |
91-175-2222200 |
|
Mobile No.: |
91-9888885355 (Mr. Umesh Kalra) |
|
Fax No.: |
91-175-2222200 |
|
E-Mail : |
sales@arlakbiotech.com |
|
Website : |
|
|
Location : |
Owned |
|
|
|
|
Corporate Office : |
SCO-11, 1st Floor, Puri Market, Near 22 No. Phatak, |
|
Location : |
Owned |
DIRECTORS
As on 24.09.2010
|
Name : |
Mr. Umesh Roshan Lal Kalra |
|
Designation : |
Director |
|
Address : |
H No# 671, Dr.
Waryam Singh Street, Mehs Gate, Nabha – 147 201, |
|
Date of Birth/Age : |
36 Years |
|
Qualification : |
Graduate |
|
Date of Appointment : |
27.04.2007 |
|
DIN No.: |
01341902 |
|
|
|
|
Name : |
Mr. Dhiraj Roshan Lal Kalra |
|
Designation : |
Director |
|
Address : |
H No# 671, Dr.
Waryam Singh Street, Mehs Gate, Nabha – 147 201, |
|
Date of Birth/Age : |
34 Years |
|
Qualification : |
Post Graduate |
|
Date of Appointment : |
27.04.2007 |
|
DIN No.: |
01341918 |
|
|
|
|
Name : |
Mrs. Jyoti Rani |
|
Designation : |
Director |
|
Address : |
200, |
|
Date of Birth/Age : |
32 Years |
|
Qualification : |
Post Graduate |
|
Date of Appointment : |
27.04.2007 |
|
DIN No.: |
02578655 |
MAJOR SHAREHOLDERS / SHAREHOLDING PATTERN
As on 24.09.2010
|
Names of Shareholders |
|
No. of Shares |
|
Umesh Kalra |
|
22500 |
|
Dhiraj Kalra |
|
4500 |
|
Jyoti Rani |
|
3000 |
|
Total |
|
30000 |
As on 24.09.2010
|
Equity Share Breakup |
|
Percentage of Holding |
|
Category |
|
|
|
Directors
or relatives of directors |
|
100.00 |
BUSINESS DETAILS
|
Line of Business : |
Trader of Pharmaceuticals. |
|
|
|
|
Terms : |
|
|
Selling : |
Cash and Credit |
|
|
|
|
Purchasing : |
Cash and Credit |
GENERAL INFORMATION
|
Suppliers : |
v
Dr. Kumar Pharmaceuticals v
Chinoin Pharmaceutical |
|
|
|
|
Customers : |
Wholesalers, Nursing Home and Trader v
Syndicate Life Sciences v
Sanex Pharmaceuticals |
|
|
|
|
No. of Employees : |
20 (Approximately) |
|
|
|
|
Bankers : |
v
Punjab National Bank, v
ICICI Bank Limited, |
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
|
|
Name : |
Harish Dhiman and Associates Chartered Accountants |
|
Address : |
1st Floor, Dhiman Mechanical Works, |
|
Tel. No.: |
91-1765-221223/ 521051 |
|
Income-tax
PAN of auditor or auditor's firm : |
AAMPD5987D |
CAPITAL STRUCTURE
As on 24.09.2010
Authorised Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
30000 |
Equity Shares |
Rs.10/- each |
Rs.0.300 million |
|
|
|
|
|
Issued, Subscribed & Paid-up Capital :
|
No. of Shares |
Type |
Value |
Amount |
|
30000 |
Equity Shares |
Rs.10/- each |
Rs.0.300 million |
|
|
|
|
|
FINANCIAL DATA
[all figures are
in Rupees Millions]
ABRIDGED BALANCE
SHEET
|
SOURCES OF FUNDS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
SHAREHOLDERS FUNDS |
|
|
|
|
|
1] Share Capital |
0.300 |
0.300 |
0.300 |
|
|
2] Share Application Money |
0.000 |
0.000 |
0.000 |
|
|
3] Reserves & Surplus |
0.057 |
0.012 |
0.000 |
|
|
4] (Accumulated Losses) |
0.000 |
0.000 |
0.000 |
|
|
NETWORTH |
0.357 |
0.312 |
0.300 |
|
|
LOAN FUNDS |
|
|
|
|
|
1] Secured Loans |
0.000 |
0.000 |
0.000 |
|
|
2] Unsecured Loans |
0.000 |
0.000 |
0.000 |
|
|
TOTAL BORROWING |
0.000 |
0.000 |
0.000 |
|
|
DEFERRED TAX LIABILITIES |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
TOTAL |
0.357 |
0.312 |
0.300 |
|
|
|
|
|
|
|
|
APPLICATION OF FUNDS |
|
|
|
|
|
|
|
|
|
|
|
FIXED ASSETS [Net Block] |
0.025 |
0.010 |
0.000 |
|
|
Capital work-in-progress |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
INVESTMENT |
0.000 |
0.000 |
0.000 |
|
|
DEFERRED TAX ASSETS |
0.001 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
CURRENT ASSETS, LOANS & ADVANCES |
|
|
|
|
|
|
Inventories |
2.425
|
1.109 |
0.000 |
|
|
Sundry Debtors |
2.079
|
1.263 |
0.000 |
|
|
Cash & Bank Balances |
0.132
|
0.050 |
0.240 |
|
|
Other Current Assets |
0.000
|
0.000 |
0.000 |
|
|
Loans & Advances |
0.000
|
0.000 |
0.040 |
|
Total
Current Assets |
4.636
|
2.422 |
0.280 |
|
|
Less : CURRENT
LIABILITIES & PROVISIONS |
|
|
|
|
|
|
Sundry Creditors |
4.193
|
1.994 |
0.000 |
|
|
Other Current Liabilities |
0.050
|
0.000 |
0.000 |
|
|
Provisions |
0.077
|
0.146 |
0.000 |
|
Total
Current Liabilities |
4.320
|
2.140 |
0.000 |
|
|
Net Current Assets |
0.316
|
0.282 |
0.280 |
|
|
|
|
|
|
|
|
MISCELLANEOUS EXPENSES |
0.015 |
0.020 |
0.020 |
|
|
|
|
|
|
|
|
TOTAL |
0.357 |
0.312 |
0.300 |
|
PROFIT & LOSS
ACCOUNT
|
|
PARTICULARS |
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
|
|
SALES |
|
|
|
|
|
|
|
Income |
8.583 |
3.778 |
0.000 |
|
|
|
Other Income |
0.143 |
0.039 |
0.000 |
|
|
|
TOTAL (A) |
8.726 |
3.817 |
0.000 |
|
|
|
|
|
|
|
|
Less |
EXPENSES |
|
|
|
|
|
|
|
Increase/ Decrease in Stock |
(1.315) |
(1.109) |
0.000 |
|
|
|
Purchase |
8.874 |
4.303 |
0.000 |
|
|
|
Trading Expenses |
0.010 |
0.021 |
0.000 |
|
|
|
Administrative Expenses |
1.086 |
0.582 |
0.000 |
|
|
|
TOTAL (B) |
8.655 |
3.797 |
0.000 |
|
|
|
|
|
|
|
|
Less |
PROFIT
BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION (A-B) (C) |
0.071 |
0.020 |
0.000 |
|
|
|
|
|
|
|
|
|
Less |
FINANCIAL
EXPENSES (D) |
0.000 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT
BEFORE TAX, DEPRECIATION AND AMORTISATION (C-D) (E) |
0.071 |
0.020 |
0.000 |
|
|
|
|
|
|
|
|
|
Less/ Add |
DEPRECIATION/
AMORTISATION (F) |
0.005 |
0.002 |
0.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT BEFORE
TAX (E-F) (G) |
0.066 |
0.018 |
0.000 |
|
|
|
|
|
|
|
|
|
Less |
TAX (H) |
0.021 |
0.006 |
0.000 |
|
|
|
|
|
|
|
|
|
|
PROFIT AFTER TAX
(G-H) (I) |
0.045 |
0.012 |
0.000 |
|
|
|
|
|
|
|
|
|
Add |
PREVIOUS
YEARS’ BALANCE BROUGHT FORWARD |
0.012 |
0.000 |
0.000 |
|
|
|
|
|
|
|
|
|
|
BALANCE CARRIED
TO THE B/S |
0.057 |
0.012 |
0.000 |
|
|
|
|
|
|
|
|
|
|
Earnings Per
Share (Rs.) |
1.50 |
0.40 |
0.00 |
|
|
Particulars |
|
31.03.2012 |
31.03.2011 |
|
Sales Turnover (Approximately) |
|
30.000 |
20.000 |
|
|
|
(New order
received) |
|
Expected Sales (2012-2013): Rs.50.000 millions
The above information has been parted by Mr. Umesh Roshan Lal Kalra
(Director).
KEY RATIOS
|
PARTICULARS |
|
31.03.2010 |
31.03.2009 |
31.03.2008 |
|
PAT / Total Income |
(%) |
0.52
|
0.31 |
0.00 |
|
|
|
|
|
|
|
Net Profit Margin (PBT/Sales) |
(%) |
0.77
|
0.48 |
0.00 |
|
|
|
|
|
|
|
Return on Total Assets (PBT/Total Assets} |
(%) |
1.42
|
0.74 |
0.00 |
|
|
|
|
|
|
|
Return on Investment (ROI) (PBT/Networth) |
|
0.18
|
0.06 |
0.00 |
|
|
|
|
|
|
|
Debt Equity Ratio (Total Liability/Networth) |
|
12.10
|
6.86 |
0.00 |
|
|
|
|
|
|
|
Current Ratio (Current Asset/Current Liability) |
|
1.07
|
1.13 |
0.00 |
LOCAL AGENCY FURTHER INFORMATION
|
Check List by Info Agents |
Available in Report (Yes / No) |
|
1) Year of
Establishment |
Yes |
|
2) Locality of
the firm |
Yes |
|
3) Constitutions
of the firm |
Yes |
|
4) Premises
details |
No |
|
5) Type of
Business |
Yes |
|
6) Line of
Business |
Yes |
|
7) Promoter’s
background |
Yes |
|
8) No. of
employees |
Yes |
|
9) Name of person
contacted |
Yes |
|
10) Designation
of contact person |
Yes |
|
11) Turnover of
firm for last three years |
Yes |
|
12) Profitability
for last three years |
Yes |
|
13) Reasons for
variation <> 20% |
Yes |
|
14) Estimation
for coming financial year |
Yes |
|
15) Capital in
the business |
Yes |
|
16) Details of
sister concerns |
No |
|
17) Major
suppliers |
Yes |
|
18) Major
customers |
Yes |
|
19) Payments
terms |
Yes |
|
20) Export /
Import details (if applicable) |
No |
|
21) Market
information |
-- |
|
22) Litigations
that the firm / promoter involved in |
-- |
|
23) Banking
Details |
Yes |
|
24) Banking facility
details |
No |
|
25) Conduct of
the banking account |
-- |
|
26) Buyer visit
details |
-- |
|
27) Financials,
if provided |
Yes |
|
28) Incorporation
details, if applicable |
Yes |
|
29) Last accounts
filed at ROC |
No |
|
30) Major Shareholders,
if available |
Yes |
OPERATIONS:
During the year
ended March 31, 2010, the company achieved a turnover of Rs.8.726 millions from
Gross Receipts from trading of Medicines.
FUTURE PROSPECTS:
The company is in the
process of expending their activities in the coming year and the Director are confident that the plans
proposed to undertaken by the company will improve the profitability of the
company.
TRADE REFERENCES:
v
Dr. Kumar Pharmaceuticals
v
Chinoin Pharmaceutical
v
Syndicate Life Sciences
v
Sanex Pharmaceuticals
FIXED ASSETS:
v Electric Items
v Furniture
WEBSITE DETAILS:
PROFILE:
Subject is a professionally managed pharmaceutical company, aim to become a top pharmaceutical company with global-level capabilities.
The company has five divisions,:- Arlak Biotech, Soigner Pharma, Moruf Lifesciences, Corazone Healthcare and Arlak Ayurveda offering more than 500 products covering all formulations (tablets, capsules, soft gelatin capsule, syrups, injectables, soap, lotion, powder, sachets, pre-filled syringes etc.) and covering all area (medicine, gynecology , dermatology, cardiology etc.)
The Company is backed by a team of professionals takes complete responsibilities and dedication in Human Health Care. They are well recognized by major Drug Magazines like CIMS, IDR, Drug Index, Pharma Biz, Drug Today, Medical Darpan, Pharma Pulse, etc.,
The company manufactures its products in an excise free zone. They offer products on monopoly basis to their business associate nationwide. With a wide product range, they have business associates in almost every state. After years of satisfaction, trust and support of their customers, the group has established itself as strong brand in the market. They offer monopoly products in best packing with unique promotional material.
Subject will develop through a management where new ideas
are encouraged and conventional thinking is challenged, and where new products
and markets are ever born in harmony with the increasingly sophisticated
desires and requirements in peoples lives. They enjoy an excellent credibility
among their esteemed customers, stokist, distributor, who know that their
Experience, Expertise and
They, not only make products that their customers want now but they also
develop new and innovative products for their customer’s future needs.
Products and services will be developed to the highest standards and quality to exceed their customers’ expectations. Their dream is to share the small gifts from everyday life with people the world over. They are committed to being on innovate, development focused company that contributes to society, builds lasting relationships with customers, and exceeds all expectations in customer satisfaction.
They endeavor to be one of the most competitive company in the industry with
emphasis on efficiency in operations, reliability for customers, affordable
prices, timely delivery and thrust on introduction of new molecules in the
marketplace.
Their core strength lies in their dream to help people live longer and
healthier lives. In pursuit of this concern, they are primarily focusing on
creating new value and benefiting to the enrichment of society through their
business.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or investigation
registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government
official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.92 |
|
|
1 |
Rs.86.03 |
|
Euro |
1 |
Rs.69.13 |
INFORMATION DETAILS
|
Information
Gathered by : |
SBA |
|
|
|
|
Report Prepared
by : |
SMN |
SCORE & RATING EXPLANATIONS
|
SCORE FACTORS |
RANGE |
POINTS |
|
HISTORY |
1~10 |
3 |
|
PAID-UP CAPITAL |
1~10 |
3 |
|
OPERATING SCALE |
1~10 |
3 |
|
FINANCIAL CONDITION |
|
|
|
--BUSINESS SCALE |
1~10 |
3 |
|
--PROFITABILIRY |
1~10 |
3 |
|
--LIQUIDITY |
1~10 |
3 |
|
--LEVERAGE |
1~10 |
3 |
|
--RESERVES |
1~10 |
3 |
|
--CREDIT LINES |
1~10 |
2 |
|
--MARGINS |
-5~5 |
- |
|
DEMERIT POINTS |
|
|
|
--BANK CHARGES |
YES/NO |
NO |
|
--LITIGATION |
YES/NO |
NO |
|
--OTHER ADVERSE INFORMATION |
YES/NO |
NO |
|
MERIT POINTS |
|
|
|
--SOLE DISTRIBUTORSHIP |
YES/NO |
NO |
|
--EXPORT ACTIVITIES |
YES/NO |
NO |
|
--AFFILIATION |
YES/NO |
NO |
|
--LISTED |
YES/NO |
NO |
|
--OTHER MERIT FACTORS |
YES/NO |
YES |
|
TOTAL |
|
26 |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively below
average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.